Oct 28: Andrew Witty on big pharmaceuticals companies

In the second part of this week's View from the Top, Andrew Witty, chief executive of GlaxoSmithKline, tells Richard Milne that the big pharma model is not broken but he insists that small integrated research and development teams are more effective than larger teams that have to deal with more bureaucracy. Mr Witty also says that the FDA needs more resource so that they can act quicker.